Berbamine inhibits the growth of TKI-resistant CML cells and primary CML cells in immunocompromised mice. BBM or imatinib was administered at 100 mg/kg body weight orally 3 times daily for 10 consecutive days, 24 hours after the subcutaneous injection of 2 × 10⁷ TKI-resistant K562 cells or primary CML cells. (A) Effects of BBM and IM on the growth of TKI-resistant tumors. (B) Effects of BBM and IM on body weight of tumor-bearing mice. (C) Effects of BBM and IM on the growth of primary CML cells at the end of experiment (day 15). (D) Effects of BBM and IM on body weight of tumor-bearing mice (n = 4; *P < .01).